The hooks of Uncaria rhynchophylla, U. sinensis and U. macrophylla are used in traditional Chinese herbal medicine as spasmolytic, analgesic and sedative treatments for many symptoms associated with hypertension and cerebrovascular disorders.
of 10 mM phosphate buffer solution pH 7.0 (A) and MeOH (B). The gradient system for analysis was A/Bϭ90/10 (0 min) →10/90 (50 min) →10/90 (60 min).
Animals Male Sprague-Dawley rats (200-250 g) were purchased from Japan SLC Inc. Animals were housed in a temperature-(22Ϯ2°C), humidity-(55Ϯ10%), and light-(8:00-20:00) controlled room with free access to distilled water and commercial rodent chow (CE-2, Clea Japan Inc., Tokyo, Japan).
Drug Administration After 7 d of feeding, food was withheld for 18 h, after which a solution of HT or HS (50 mg/kg) in propylene glycol was orally administered by direct stomach intubation at a constant volume of 1 ml/kg body weight. Animals were allowed free access to water and sugar during the experiments. Experimental procedures were conducted in accordance with the protocols approved by the Committee of Animal Experiments of Tohoku Pharmaceutical University.
Urine Samples Urine samples were collected for 72 h at 24-h intervals after oral administration of HT and HS (50 mg/kg) using a metabolic cage. Each urine sample was filtered through a 0.45-mm-membrane filter, and 20 ml of the sample was subjected to HPLC.
Bile Sample After rats were anesthetized by intraperitoneal injection of sodium pentobarbital (20 mg/kg), the bile duct was exposed and a small incision was made in the duct wall with microspring scissors. A catheter, fashioned from a 500-mm segment of polyethylene tube (ID 0.50 mm, OD 1.00 mm, Kunii) welded to a 40-mm polyethylene segment (ID 0.28 mm, OD 0.61 mm, Becton), was introduced through the incision and advanced 10 mm. After the catheter was tunneled to exit via a small hole in the skin on the dorsal side of the neck, the abdominal incision was closed using sutures and wound clipping. The exteriorized catheter was connected to a cannula swivel (model TCS2-21, Tsumura; Tokyo, Japan), and the rats were placed in a plastic cage with a freemoving system (Tsumura) that rotated through 360°in the horizontal plane and through 180°in the vertical plane, thus giving the animals freedom of movement. One hour after preparation, HT and HS (50 mg/kg) were orally administered. Bile samples were collected in tubes chilled with ice water for 72 h at 24-h intervals. Samples (20 ml) were filtered through a 0.45-mm-filter membrane and subjected to HPLC.
Enzymatic Hydrolysis of Urine Sample Urine samples were transferred to test tubes containing 5.0 ml of 0.2 M sodium acetate buffer (pH 5.5) and 50 ml of b-glucuronidase solution, and were incubated at 37°C for 24 h. The incubated solution was extracted three times with ethyl acetate (20 ml). The organic layer was then evaporated to dryness at 40°C. The residue was dissolved in 1.0 ml of methanol and a 20-ml aliquot was subjected to HPLC.
Isolation of Urinary and Biliary Metabolites For urinary and biliary metabolite isolation, total administration of HT and HS were as follows: urine samples, HT 280 mg and HS 285 mg; bile samples, HT 84 mg and HS 82 mg. Urine (400 ml) and bile (100 ml) obtained from 20 and 6 rats, respectively, was successively subjected to Sephadex LH-20 with MeOH, and fractions containing metabolites were evaporated to dryness under reduced pressure at 40°C. The residue was dissolved in a small amount of methanol and was further purified by preparative HPLC under the following conditions: column, TSKgel ODS-120T (300ϫ7.8 mm i.d., 5 mm particle size, Tosoh Company Ltd., Tokyo, Japan); mobile phase, H 2 O (solvent A) and methanol (solvent B), linear gradient system, A/Bϭ90/10 (0 min) →10/90 (50 min). Flow rate was 2.0 ml/min at room temperature. Each metabolite fraction was evaporated to dryness at 40°C in vacuo to afford HT1 (10 mg), HT2 (5 mg), HT3 (5 mg), HT4 (5 mg), HS1 (15 mg), HS2 (5 mg) HS3 (3 mg) and HS4 (10 mg). These compounds (HT1-3 and HS1-3) were used as authentic samples for the quantitative and qualitative analysis of metabolites.
Incubation of HT and HS with Rat Liver Microsomes The standard incubation mixture consisted of rat liver microsomes (0.2-3.0 mg protein/ml), and 100 mM HT and HS (dissolved in DMSO) in a final volume of 1.0 ml of 100 mM PBS (pH 7.4) containing an NADPH-generating system (0.67 mg/ml MgCl 2 , 0.5 mM NADP ϩ , 5 mM glucose 6-phosphate, and 0.5 units of glucose 6-phosphate dehydrogenase/ ml). Incubation was carried out at 37°C for 1 h in a test tube and was terminated by adding 100 ml of acetonitrile and cooling on ice. The mixture was vortexed for 1 min and was then centrifuged at 10000ϫg for 10 min. Reaction supernatant was filtered through a 0.45-mm membrane filter, and 20 ml was then subjected to HPLC. SKF-525A and cimetidine (62.5-500 mM) were dissolved in DMSO such that the final concentration of the vehicle in the incubation mixture was 1.0%. Inhibitors were added to incubation mixtures (0.5 mg protein/ml) containing the NADPH-generating system 15 min before addition of substrates at 25 mM, and activity was compared to that in identical incubation mixtures without inhibitor. The concentrations of chemical CYP inhibitors were selected according to the methods of previous reports. [13] [14] [15] [16] These incubations were performed in triplicate. Calibration Curves Calibration curves were prepared by spiking predose urine, bile and PBS with known amounts of metabolites in a final concentration range of 12.20ϫ10 Ϫ1 mg/ml-12.2ϫ10 mg/ml (in urine and bile samples) or 11.75ϫ10
Ϫ2 mg/ml-58.75ϫ10 Ϫ1 mg/ml (in incubation solutions). Metabolite concentrations were determined from the peak area using the equation for linear regression obtained from the calibration curves.
Recovery Known amounts of metabolites (0.51-0.10 mg) were added to blank urine (20 ml), bile (10 ml) and PBS (100 ml), and were subjected to determination. Recoveries were calculated by comparing experimental values with corresponding theoretical values. Metabolite recoveries from rat urine bile, and PBS were found to be 90. 7 
RESULTS

Identification of Metabolites
For preliminary detection of HT and HS metabolites in rat urine and bile, HPLC fingerprint profiles of these metabolites were developed using a photodiode array detector. With phosphate buffer solution (pH 7.0) and methanol solvent, three metabolites were detected in urine samples after oral administration of HT and HS at 50 mg/kg (HT1-3 and HS1-3, respectively), as shown in Fig. 1 . The retention times for the metabolites were as follows: HT1 Ϫ26 min, HT2 Ϫ36 min, HT3 Ϫ44 min, HS1 Ϫ28 min, HS2 Ϫ38 min, and HS3 Ϫ46 min. On the other hand, analysis of the bile samples revealed the presence of a single metabolite for each compound (HT4 Ϫ26 min and HS4 Ϫ28 min). Representative chromatograms of the bile samples are shown in Fig. 2 .
The IR spectra of all metabolites exhibited absorption due ) and ester carbonyl groups (1692-1702 cm
Ϫ1
), but Wenkert-Bohlmann bands (2700-2800 cm
) were not observed. On the CD spectra, a negative Cotton effect in the longer wavelength region between 266-324 nm was observed. 1 H-and 13 C-NMR spectra also suggested that all metabolites were Corynanthe-type indole alkaloids with the pseudo configuration (C3Hb, C15Ha, C20Hb), similar to the parent compounds. 17) Metabolite HT2 was obtained as a pale yellow amorphous powder, [a] ϩ95.0°. High-resolution EIMS analysis gave an m/z of 382.1876 [M] ϩ (DϪ1.6 mmu) and established the molecular formula as C 22 C-NMR spectrum of HT2 with HT showed that the C-11 signal shifted upfield by 30.8 ppm, accompanied by downfield shifts of C-10 (13.5 ppm) and C-12 (6.0 ppm). Accordingly, a substitution at position 11 was assumed. The tentative structure was further supported by C-H COSY and 1 H-detected heteronuclear multiple bond correlation (HMBC) experiments, and HT2 was concluded to be 11-hydroxyhirsuteine.
Metabolite C-NMR spectra of HS2 and HS indicated that the C-11 signal of HS2 shifted upfield by 30.4 ppm, accompanied by downfield shifts of C-10 (10.3 ppm) and -12 (13.8 ppm), indicating that the hydroxy group is situated at C-11. This tentative structure was supported by 2D-NMR spectra (C-H COSY, HMBC). Thus, HS2 was determined to be 11-hydroxyhirsutine.
Metabolite HT1 was obtained as an amorphous powder, [a] ϩ18.0°. FAB-MS showed a pseudomolecular ion peak at m/z 557 [MϪH] Ϫ corresponding to hydroxyhirsuteine monoglucuronide in addition to a fragment ion peak at m/z 381 [MϪHϪGlcUA] Ϫ . The molecular formula, C 28 H 33 N 2 O 10 , was determined based on the molecular ion peak observed on FAB-MS and by HR-FAB-MS measurement. Enzymatic hydrolysis of HT1 with b-glucuronidase gave a product that was identified as 11-hydroxyhirsuteine based on its retention time and UV spectrum during HPLC relative to HT2.
1 Hand . The molecular formula, C 28 H 35 N 2 O 10 , was determined based on the molecular ion peak observed on FAB-MS and by HR-FAB-MS measurement. Enzymatic hydrolysis of HS1 with b-glucuronidase gave an aglycone, which was assumed to be 11-hydroxyhirsutine from its HPLC behavior. Furthermore, the NMR spectrum of HS1 was superimposable on that of 11-hydroxyhirsutine, except for the b-glucuronic acid signal. The location of the glucuronic acid moiety was confirmed by HMBC to be between the anomeric proton (H-1Ј) at d 4.91 and C-11 at d 152.8 for the 11-hydroxyhirsutine moiety. Accordingly, HS1 was identified as 11-hydroxyhirsutine-11-O-b-D-glucuronide.
Metabolites HT3, HS3, HT4 and HS4 were confirmed to be HT, HS, 11-hydroxyhirsuteine-11-O-b-D-glucuronide and 11-hydroxyhirsutine-11-O-b-D-glucuronide, respectively, based on direct comparison of spectroscopic data with authentic samples or HT1 and HS1 isolated from urine sample.
The chemical structures of these metabolites are shown in Fig. 3 .
Quantification of Metabolites The urinary excretion profiles of metabolites after administration of 50 mg/kg HT and HS are shown in Table 1 . The cumulative amounts of metabolites (HT1-HT3 and HS1-HS3) excreted in urine within 72 h corresponded to 9.38Ϯ2.19%, 3.49Ϯ1.32% and 1.07Ϯ0.28% of HT dose administered, and 16.58Ϯ2.44%, 8.73Ϯ1.85% and 0.66Ϯ0.19% of HS dose administered. The total cumulative mean was 13.94Ϯ3.79% and 25.97Ϯ4.48% of HT and HS doses administered, respectively.
The biliary excretion of metabolites is shown in Table 2 . The total cumulative amounts of HT1 and HS1 excreted within 72 h corresponded to 35.02Ϯ1.29% and 45.62Ϯ 5.35% (meanϮS.E., nϭ6) of HT and HS doses administered, respectively.
Incubation of HT and HS HPLC analysis of the HT and HS solutions after incubation with rat liver microsomes revealed the presence of metabolites. These metabolites were identified as 11-hydroxy metabolites based on comparisons of retention time and UV spectral data with those of authentic samples. As shown in Fig. 4 , the 11-hydroxylation activity was found to increase with microsomal protein in a concentration-dependent manner, up to about 0.5 mg/ml. Therefore, the inhibition study was performed at a protein concentration of 0.5 mg/ml. The effects of nonselective and CYP2C inhibitors on the formation of 11-hydroxy metabolites are presented in Fig. 5 . SKF-525A (62.5-500 mM), a nonselective CYP inhibitor, inhibited the hepatic microsomal metabolism of HT and HS by 28-83% and 68-76%, respectively. Cimetidine (62.5-500 mM), a CYP2C inhibitor, also decreased the HT and HS 11-hydroxy formation by 31-65% and 18-63%, when compared with inhibitor-free controls.
DISCUSSION
The hooks of Uncaria rhynchophylla, sinensis, and macrophylla are used in traditional Chinese herbal medicines as spasmolytic, analgesic and sedative treatments for various symptoms associated with hypertension and cerebrovascular disorders. 1, 2) HT and HS were isolated as major active indole alkaloids from the Uncaria species. [7] [8] [9] To date, however, no studies have been carried out to determine their metabolic fates. Therefore, we studied the metabolism and excretion of these active indole alkaloids in rats.
Using an HPLC system with a photodiode array detector, we confirmed that three metabolites (HT1-3 and HS1-3) were present in the urine of rats orally administered HT and HS. The chemical structures of these metabolites were determined to be 11-hydroxyhirsuteine-11-O-b-D-glucuronide (HT1), 11-hydroxyhirsuteine (HT2), 11-hydroxyhirsutine-11-O-b-D-glucuronide (HS1), 11-hydroxyhirsutine (HS2) and the unchanged parent compounds HT (HT3) and HS (HS3) based on direct isolation in urine samples and spectroscopic data. On the other hand, the chromatograms of bile samples showed only the presence of a single metabolite (HT4 and HS4) each for HT and HS. The spectroscopic and chemical data of the metabolites were consistent with the urinary metabolites HT1 and HS1. Thus, after oral administration in rats, it appears that HT and HS undergo 11-hydroxylation of Quantitative analysis demonstrated that the urinary excretion of HT and HS was terminated within 24 h of oral administration, while the metabolites were excreted for up to 72 h. The total cumulative amounts of the metabolites and unchanged HT and HS in the urine were approximately 14 and 26% of the doses, respectively, and the unchanged forms accounted for only 1%. On the other hand, the total cumulative biliary excretion of HT and HS glucuronides was 35 and 46%, respectively, and most of this excretion occurred within 24 h. These results suggest that orally administered HT and HS are predominantly metabolized to the corresponding 11-hydroxy forms, followed by b-glucuronidation, and that the oral bioavailabilities of HT or HS, per se, are relatively low. Further detailed study of plasma concentrations of HT and HS is required to clarify this notion. Orally administered phenolic compounds, particularly those with low polarity, undergo glucuronide and sulfate conjugation in the intestinal mucosa, the liver and other tissues. We previously reported that paeonol (2-hydroxy-4-methoxyacetophenone) orally administered to rats was excreted in the bile and urine as four sulfated metabolites. 18) However, in the present study, we were unable to detect sulfates in the bile and urine after HT and HS administration. Based on these results, we speculate that both alkaloids are high-affinity substrates for glucuronidation rather than sulfation, and that the high molecular weight and high polarity of the glucuronides promote the excretion of the alkaloids in bile. This would result in the long-term accumulation of both alkaloid metabolites in the body.
The present study clearly showed that rat liver microsome enzymes catalyzed the mono-hydroxylation of HT and HS. Hydroxylation (phase-1 metabolism) is catalyzed by liver microsome enzymes such as CYP1A, 2C, 2B, and 2D in rat. Among these, the CYP2C family is the major isoforms in rats 19, 20) and efficiently catalyzes the 7-hydroxy formation of warfarin.
21) Thus, we used chemical CYP inhibitors, SKF 525A and cimetidine, to identify whether the CYP2C family is related to the HT and HS hydroxylation. As expected, the addition of cimetidine, as well as SKF 525A, decreased the 11-hydroxy formation of HT and HS, which suggests that CYP2C enzymes are involved, at least in part, in the specific 11-hydroxylation of HT and HS.
Le Verge et al. reported that yohimbine, which contains a tetracyclic indole alkaloid skeleton similar to those of HT and HS, is metabolized to 10-and 11-monohydroxy forms in humans.
22) The 11-hydroxyyohimbine, but not 10-hydroxy, possesses the same a 2 -adrenoceptor blocking activity as yohimbine. 23) Furthermore, the 11-hydroxyyohimbine is highly present in plasma and exhibits a longer elimination half-life than the parent drug (6 h vs. 1 h). 22) Ozaki reported that HT and HS have hypothermic effects in mice (30 or 60 mg/kg, i.p.); however, these alkaloids exhibit prolonged hypothermic effects when compared with aminopyrine, the positive control. 8) Although HT and HS possess a central depressive and vasodilative effect in addition to hypothermia induction activity, the involvement of 11-hydroxymetabolites in these activities cannot be excluded. Further work is necessary to determine whether hydroxy metabolites are involved in the pharmacological effects of HT, HS.
CONCLUSION
In this investigation, two mono-hydroxylated phase-1 metabolites of HT and HS were isolated and identified as 11-hydroxyindoles based on spectroscopic data. To our knowledge, these are the first data relating to the metabolism of HT and HS in vivo and in vitro. The present results will facilitate an improved understanding of pharmacokinetics and pharmacodynamics of HT and HS. 
